V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016562 | 160016379 | 1.57 | 31 | null | 2020-01-13 | 2020-01-15 | Cyclophosphamide + Topotecan | 02 | null | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 100895540 |
| 160016564 | 160016380 | 0 | null | Curative (C) | null | 2020-01-31 | CEMIPLIMAB | 02 | N | EW EUROEWING 2012 ARM A VAC | 100599975 |
| 160016568 | 160016381 | 1.76 | 68.9 | Curative (C) | 2019-03-08 | 2019-03-08 | IVADo | 02 | N | EW EUROEWING 2012 ARM A VAI | 100064632 |
| 160016570 | 160016382 | 0 | 0 | Curative (C) | 2016-07-26 | 2017-02-03 | Rucaparib | 02 | N | NB HRNBL-1 COJEC IND COURSE C | 100711765 |
| 160016572 | 160016383 | 1.57 | 63.4 | Palliative (P) | 2017-01-27 | 2017-01-27 | MELPHALAN | 02 | N | IPILIMUMAB + NIVOLUMAB | 101496620 |
| 160016573 | 160016384 | 1.74 | 83 | Neo-adjuvant (N) | 2019-12-09 | 2019-12-22 | Fulvestrant + Ribociclib | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100506796 |
| 160016576 | 160016385 | 1.72 | 108.5 | null | 2020-08-08 | 2020-10-12 | NB HRNBL-1 COJEC Ind COURSE C | N | null | CISPLATIN + DOXORUBICIN + METHOTREXATE | 101269451 |
| 160016581 | 160016386 | 1.82 | 78.6 | Curative (C) | 2018-11-07 | 2018-11-14 | PEMBROLIZUMAB | 02 | N | RMS 2005 TRIAL | 101110125 |
| 160016583 | 160016387 | 1.77 | 34 | Palliative (P) | 2020-07-06 | 2020-07-27 | Doxorubicin + Ifosfamide | N | N | STS NON-RHABDO EPSSG 2005 IFOS | 101370304 |
| 160016584 | 160016388 | 0.82 | 58.2 | Palliative (P) | 2020-02-06 | 2020-02-23 | EW EuroEwing 2012 Arm A VAC | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100622382 |
| 160016585 | 160016389 | 0 | 89.1 | Curative (C) | 2018-11-06 | 2019-07-19 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 100061385 |
| 160016587 | 160016390 | 1.64 | 14.8 | Neo-adjuvant (N) | 2020-07-16 | 2021-07-24 | Doxorubicin + Ifosfamide | 02 | N | NOT MATCHED | 101439690 |
| 160016589 | 160016391 | 1.65 | 100.4 | Curative (C) | 2022-02-18 | 2022-02-25 | NB HRNBL-1 Isotretinoin | 02 | N | RITUXIMAB | 100705812 |
| 160016596 | 160016392 | 0 | 23.5 | Palliative (P) | 2019-07-06 | 2020-02-02 | STS Rhabdo RMS 2005 Vin Cyclo | 2 | N | TRIAL | 101238130 |
| 160016600 | 160016393 | 1.62 | null | null | 2020-01-16 | 2020-02-13 | Olaratumab | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 100627325 |
| 160016601 | 160016394 | 0 | 92.9 | 03 | 2017-03-20 | 2017-08-19 | CABOZANTINIB | 02 | N | CONFIRM TRIAL | 101288706 |
| 160016613 | 160016395 | 1.77 | 12 | null | 2017-06-20 | 2017-07-10 | STS Rhabdomyosarcoma RMS 2005 IVAVV | Y | null | OLARATUMAB | 101487963 |
| 160016631 | 160016397 | 1.74 | 74.6 | Curative (C) | 2019-01-06 | 2019-02-03 | null | 02 | N | GEMCITABINE | 100602223 |
| 160016634 | 160016398 | 0 | 121.4 | null | 2018-08-11 | 2018-08-13 | GemCarbo Days 1+8 | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101340491 |
| 160016636 | 160016399 | 1.58 | 66.7 | null | 2020-10-20 | 2020-12-07 | EW EuroEwing 2012 Arm B IE | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100921383 |
| 160016640 | 160016400 | null | 82 | null | 2018-03-09 | 2018-03-19 | CEDIRANIB | 99 | null | EW EUROEWING 2012 ARM B VC | 100225927 |
| 160016641 | 160016401 | 0 | 104 | Curative (C) | 2016-10-11 | 2017-05-05 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 100119618 |
| 160016646 | 160016402 | 0 | 64.2 | Neo-adjuvant (N) | 2019-07-04 | 2019-11-26 | FLUOROURACIL + IRINOTECAN | 02 | N | GEMCITABINE | 100730705 |
| 160016655 | 160016403 | null | 76 | Palliative (P) | 2016-12-13 | 2019-11-05 | Cyclophosphamide + Topotecan | 02 | N | NB BEACON TEMOZOLOMIDE AND TOPOTECAN | 100203446 |
| 160016657 | 160016404 | 1.66 | 75 | null | 2019-07-03 | 2019-08-13 | EW EuroEwing 2012 Arm B IE | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101570378 |
| 160016660 | 160016405 | 1.78 | 84.9 | null | 2021-02-02 | 2022-04-04 | Trial Unspecified | 02 | null | CYCLOPHOSPHAMIDE + VINCRISTINE | 101339215 |
| 160016662 | 160016406 | null | null | null | 2017-11-16 | 2017-11-17 | EW EuroEwing 2012 Arm A VAI | 02 | null | EURO-EWING | 101470002 |
| 160016666 | 160016407 | 1.71 | 17.8 | Curative (C) | 2018-05-12 | 2018-11-10 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | RMS 2005 TRIAL | 101163761 |
| 160016669 | 160016408 | 1.62 | 81.2 | null | 2017-03-24 | 2020-07-09 | Gemcitabine day 1&8 | 02 | null | BORTEZOMIB + DARATUMUMAB | 101742044 |
| 160016671 | 160016409 | 0 | 47.6 | Palliative (P) | 2020-01-04 | 2020-01-09 | MELPHALAN + THALIDOMIDE | 02 | N | GEMCITABINE | 100844767 |
| 160016675 | 160016410 | 1.68 | 69.9 | Palliative (P) | 2020-04-08 | 2020-05-13 | IPM | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 100872158 |
| 160016681 | 160016411 | 1.71 | 135 | Curative (C) | 2016-04-28 | 2016-06-29 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 100640432 |
| 160016686 | 160016412 | null | 78.1 | null | 2016-11-10 | 2017-07-03 | Ifosfamide | 02 | null | ETOPOSIDE | 100022000 |
| 160016692 | 160016413 | 1.62 | 103 | Curative (C) | 2020-10-12 | 2020-10-12 | Docetaxel | 02 | N | NB HRNBL-1 ISOTRETINOIN | 100161840 |
| 160016695 | 160016414 | 1.76 | 68.9 | Palliative (P) | 2018-05-30 | 2018-06-01 | MELPHALAN | 02 | null | TRIAL | 100398565 |
| 160016698 | 160016415 | 1.56 | 17.1 | Palliative (P) | 2019-12-07 | 2019-12-07 | NB HRNBL-1 Isotretinoin | 02 | N | PROMISE-MESO TRIAL | 100699335 |
| 160016706 | 160016416 | 0 | 55.1 | Neo-adjuvant (N) | 2020-01-28 | 2020-02-03 | CABOZANTINIB | N | null | BEVACIZUMAB + CARBO + PACLITAXEL | 100928396 |
| 160016710 | 160016417 | null | 78.5 | Neo-adjuvant (N) | 2016-12-17 | 2016-12-17 | Trial Unspecified | 02 | N | PAZOPANIB | 100954690 |
| 160016711 | 160016418 | 0.89 | 10 | Neo-adjuvant (N) | 2017-11-12 | 2017-12-10 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100851842 |
| 160016712 | 160016419 | 1.83 | 46.5 | null | 2016-07-08 | 2016-12-10 | Ifosfamide 3g/m2 5 day | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100683768 |
| 160016718 | 160016420 | null | 66.7 | Curative (C) | 2016-12-22 | 2016-12-29 | Ifosfamide 3g/m2 5 day | 02 | null | TRIAL | 100521302 |
| 160016720 | 160016421 | 1.67 | null | Curative (C) | 2017-10-08 | 2018-07-20 | null | 01 | null | ETOPOSIDE + IFOSFAMIDE | 100139404 |
| 160016721 | 160016422 | null | 68.3 | Curative (C) | 2018-08-03 | 2019-04-09 | Ifosfamide | 02 | N | RIBOCICLIB | 100121389 |
| 160016722 | 160016423 | 1.62 | 104 | Curative (C) | 2018-02-07 | 2019-10-07 | null | 02 | N | TRIAL | 101781879 |
| 160016727 | 160016424 | 0 | 76.8 | Curative (C) | 2019-09-28 | 2020-03-24 | PROMISE-MESO TRIAL | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100434959 |
| 160016728 | 160016425 | 1.7 | 41.4 | null | 2019-11-02 | 2019-11-04 | Doxorubicin + Ifosfamide | 02 | null | DACARBAZINE + GEMCITABINE | 101189672 |
| 160016730 | 160016426 | 1.76 | 10 | null | 2019-09-04 | 2019-09-15 | EW EuroEwing 2012 Arm A VAC | 01 | null | NB HRNBL-1 COJEC IND COURSE C | 100155044 |
| 160016731 | 160016427 | 1.72 | 89 | null | 2016-07-13 | 2016-08-17 | NB Low/Intermed risk guidelines CADO | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 101509788 |
| 160016732 | 160016428 | 1.56 | 125 | Curative (C) | 2019-04-02 | 2019-04-18 | Melpahan IV Low dose | 02 | N | NIRAPARIB | 100892266 |
| 160016734 | 160016429 | 1.83 | 114.6 | Palliative (P) | 2018-02-20 | 2018-02-23 | EW EuroEwing 2012 Arm A VAI | 02 | null | TEMOZOLOMIDE | 100068510 |